Overview

Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer

Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well everolimus works in treating patients with locally advanced or metastatic thyroid cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Yonsei University
Treatments:
Everolimus
Sirolimus